Altered serum levels of adipokines and insulin in Probable Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 41, Issue 4, 2014, Pages 525-533

  Khemka, Vineet Kumar ^a   Bagchi, Debajit ^a   Bandyopadhyay, Kausik ^a   Bir, Aritri ^a   Chattopadhyay, Mrittika ^a   Biswas, Atanu ^b   Basu, Debasis ^a   Chakrabarti, Sasanka ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b Department of Neurosurgery   (India)

Author keywords

Adiponectin; Alzheimer's disease; Amyloid ; Insulin; Leptin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; TRIACYLGLYCEROL;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD BIOCHEMISTRY; BLOOD SAMPLING; BODY MASS; BRAIN ATROPHY; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOASSAY; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD ANALYSIS; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE;

ADIPONECTIN; AGED; ALZHEIMER DISEASE; BLOOD CHEMICAL ANALYSIS; FEMALE; HUMANS; IMMUNOASSAY; INSULIN; LEPTIN; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES;

EID: 84922677289     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140006     Document Type: Article

References (61)

1. Qiu C, Fratiglioni L (2011) Epidemiology of dementia. In Dementia Treatments and Developments, McNamara P, ed. ABC-CLIO, California, pp. 1-33.
2. Reitz C, Brayne C, Mayeux R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7, 137-152.
3. Strooper BD (2010) Proteases and proteolysis in Alzheimer disease: A multifactorial view on the disease process. Physiol Rev 90, 465-494.
4. Dong S, Duan Y, Hu Y, Zhao Z (2012) Advances in the patho-genesis of Alzheimer's disease: A re-evaluation of amyloid cascade hypothesis. Transl Neurodegener 1, 18.
5. Leuner K, Muller WE, Reichert AS (2012) From mitochon-drial dysfunction to amyloid beta formation: Novel insights into the pathogenesis of Alzheimer's disease. Mol Neurobiol 46, 186-193.
6. Mangialasche F, Polidori MC, Monastero R (2009) Biomarkers ofoxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Aging Res Rev 8, 285-305.
7. Gotz J, Ittner LM (2008) Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 9, 532-544.
8. Young JE, Goldstein LS (2012) Alzheimer's disease in a dish: Promisesand challengesofhuman stemcell models. Hum Mol Genet 21, R82-R89.
9. Ray L, Khemka VK, Behera P, Bandyopadhyay K, Pal S, Pal K, Basu D, Chakrabarti S (2013) Serum homocys-teine, dehydroepiandrosterone sulphate and lipoprotein (a) in Alzheimer's disease and vascular dementia. Aging Dis 4, 57-64.
10. Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ (1996) Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 47, 454-461.
11. Burns JM, Johnson DK, Watts A, Swerdlow RH, Brooks WM (2010) Reduced lean mass in early Alzheimer disease and its association with brain atrophy. Arch Neurol 67, 428-433.
12. Guerin O, Andrieu S, Schneider SM, Milano M, Boulahssass R, Brocker P, Vellas B (2005) Different modes of weight loss in Alzheimer disease: A prospective study of 395 patients. Am J Clin Nutr 82, 435-441.
13. Lee EB (2011) Obesity, leptin, and Alzheimer's disease. Ann NY Acad Sci 1243, 15-29.
14. Thundyil J, Pavlovski D, Sobey CG, Arumugam TV (2012) Adiponectin receptor signalling in the brain. Br J Pharmacol 165, 313-327.
15. Neumann KF, Rojo L, Navarrete LP, Farias G, Reyes P, Maccioni RB (2008) Insulin resistance and Alzheimer's disease: Molecular links & clinical implications. Curr Alzheimer Res 5, 438-447.
16. Une K, Takei YA, Tomita N, Asamura T, Ohrui T, Furukawa K, Arai H (2011) Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer's disease. Eur J Neurol 18, 1006-1009.
17. Burns JM, Donnelly JE, Anderson HS, Mayo MS, Spencer-Gardner L, Thomas G, Cronk BB, Haddad Z, Klima D, Hansen D, Brooks WM (2007) Peripheral insulin and brain structure in early Alzheimer disease. Neurology 69, 1094-1104.
18. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257, 79-83.
19. Tasaka Y, Yanagisawa K, Iwamoto Y (1997) Human plasma leptin in obese subjects and diabetics. Endocr J 44, 671-676.
20. Soodini GR (2004) Adiponectin and leptin in relation to insulin sensitivity. Metab Syndr Relat Disord 2, 114-123.
21. Holden KF, Lindquist K, Tylavsky FA, Rosano C, Harris TB, Yaffe K (2009) Serum leptin level and cognitionin the elderly: Findings from the Health ABC Study. Neurobiol Aging 30, 1483-1489.
22. Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, Harris TB, Roubenoff R, Auerbach S, DeCarli C, Wolf PA, Seshadri S (2009) Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 302, 2565-2572.
23. Bigalke B, Schreitmuller B, Sopova K, Paul A, Stransky E, Gawaz M, Stellos K, Laske C (2011) Adipocytokines and CD34 progenitor cells in Alzheimer's disease. PLoS One 6, e20286.
24. Warren MW, Hynan LS, Weiner MF (2012) Lipids and adipokines as risk factors for Alzheimer's disease. J Alzheimers Dis 29, 151-157.
25. Teixeira AL, Diniz BS, Campos AC, Miranda AS, Rocha NP, Talib LL, Gattaz WF, Forlenza OV (2013) Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer's disease. Neuromolecular Med 15, 115-121.
26. Van Himbergen TM, Beiser AS, Ai M, Seshadri S, Otokozawa S, Au R, Thongtang N, Wolf PA, Schaefer EJ (2012) Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: Results from the Framingham Heart Study. Arch Neurol 69, 594-600.
27. Beccano-Kelly D, Harvey J (2012) Leptin: A novel therapeutic target in Alzheimer's disease? Int J Alzheimers Dis 2012, 594137.
28. Tezapsidis N, Johnston JM, Smith MA, Ashford JW, Casadesus G, Robakis NK, Wolozin B, Perry G, Zhu X, Greco SJ, Sarkar S (2009) Leptin: A novel therapeutic strategy for Alzheimer's disease. J Alzheimers Dis 16, 731-740.
29. Greco SJ, Sarkar S, Johnston JM, Tezapsidis N (2009) Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem Biophys Res Commun 380, 98-104.
30. Kadowaki T, Yamauchi T, Kubota N (2008) The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett 582, 74-80.
31. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116, 1784-1792.
32. Thundyil J, Tang SC, Okun E, Shah K, Karamyan VT, Li Yi, Woodruff TM, Taylor SM, Jo DG, Mattson MP, Arumugam TV (2010) Evidence that adiponectin receptor 1 activation exacerbates ischemic neuronal death. Exp Transl Stroke Med 2, 15.
33. Chan KH, Lam KS, Cheng OY, Kwan JS, Ho PW, Cheng KK, Chung SK, Ho JW, Guo VY, Xu A (2012) Adiponectin is protective against oxidative stress induced cytotoxicity in amyloid-beta neurotoxicity. PLoS One 7, e52354.
34. Kopf D, Frolich L (2009) Risk of incident Alzheimer's disease in diabetic patients: A systematic review of prospective trials. J Alzheimers Dis 16, 677-685.
35. Vagelatos NT, Eslick GD (2013) Type 2 diabetes as a risk factor for Alzheimer's disease: The confounders, interactions, and neuropathology associated with this relationship. Epidemiol Rev 35, 152-160.
36. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2011) Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol 225, 54-62.
37. Bosco D, Fava A, Plastino M, Montalcini T, Pujia A (2011) Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J Cell Mol Med 15, 1807-1821.
38. Citron M (2002) Alzheimer's disease: Treatment in discovery and development. Nat Neurosci 5, 1055-1057.
39. Peila R, Rodriguez BL, Lauren LJ (2002) Type 2 diabetes, diabetes, Apo E gene and the risk for dementia and related pathogenesis: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262.
40. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM (2009) Diabetes mellitus and risk of dementia: The Rotterdarm Study. Neurology 53, 1937-1942.
41. Furiya Y, Ryo M, Kawahara M, Kiriyama T, Morikawa M, Ueno S (2013) Renin-angiotensin system blockers affect cognitive decline and serum adipocytokines in Alzheimer's disease. Alzheimers Dement 9, 512-518.
42. Moreira RO, Campos SC, Soldera AL (2013) Type 2 diabetes mellitus and Alzheimer's disease: From physiopathology to treatment implications. Diabetes Metab Res Rev, doi: 10.1002/dmrr.2442
43. Vignini A, Giulietti A, Nanetti L, Raffaelli F, Giusti L, Mazzanti L, Provinciali L (2013) Alzheimer's disease and diabetes: New insights and unifying therapies. Curr Diabetes Rev 9, 218-227.
44. Paragh G, Balla P, Katona E, Seres I, Egerházi A, Degrell I (2002) Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 252, 63-67.
45. Sabbagh M, Zahiri HR, Ceimo J, Cooper K, Gaul W, Connor D, Sparks DL (2004) Is there a characteristic lipid profile in Alzheimer's disease? J Alzheimers Dis 6, 585-589.
46. Puglielli L, Tanzi RE, Kovacs DM (2003) Alzheimer's disease: The cholesterol connection. Nat Neurosci 6, 345-351.
47. Leoni V, Caccia C (2011) Oxysterols as biomarkers in neurodegenerative diseases. Chem Phys Lipids 164, 515-524.
48. Gamba P, Testa G, Sottero B, Gargiulo S, Poli G, Leonarduzzi G(2012)Thelink between altered cholesterol metabolism and Alzheimer's disease. Ann N Y Acad Sci 1259, 54-64.
49. Evans RM, Emsley CL, Gao S, Sahota A, Hall KS, Farlow MR, Hendrie H (2000) Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: A population-based study of African Americans. Neurology 54, 240-242.
50. Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J, Farlow MR (2004) Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology 62, 1869-1871.
51. Kivipelto M, Laakso MP, Tuomilehto J, Nissinen A, Soininen H (2002) Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: Potential for pharmacological intervention. CNS Drugs 16, 435-444.
52. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, Girones X, Henry TL, Matsubara E, Zambon D, Wolozin B, Sano M, Cruz-Sanchez FF, Thal LJ, Petanceska SS, Refolo LM (2003) Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloidpathology. Neurology 61, 199-205.
53. Lahiri DK, Maloney B (2010) Beyond the signaling effect role of amyloid ß42 on the processing of APP, and its clinical implications. Exp Neurol 225, 51-54.
54. Sambamurti K, Granholm AC, Kindy MS, Bhat NR, Greig NH, Lahiri DK, Mintzer JE (2004) Cholesterol and Alzheimer's disease: Clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets 5, 517-528.
55. Lahiri DK, Maloney B, Zawia NH (2009) The LEARn model: An epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry 14, 992-1003.
56. Wood WG, Igbavboa U, Eckert GP, Johnson-Anuna LN, Muller WE (2005) Is hypercholesterolemia a risk factor for Alzheimer's disease? Mol Neurobiol 31, 185-192.
57. Shepardson NE, Shankar GM, Selkoe DJ (2011) Cholesterol level and statin usein Alzheimer disease: I. Review of epidemi-ological and preclinical studies. Arch Neurol 68, 1239-1244.
58. Shepardson NE, Shankar GM, Selkoe DJ (2011) Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol 68, 1385-1392.
59. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 257-262.
60. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
61. Benomar Y, Naour N, Aubourg A, Bailleux V, Gertler A, Djiane J, Guerre-Millo M, Taouis M (2006) Insulin and lep-tin induce Glut4 plasma membrane translocation and glucose uptake in a human neuronal cell line by a phosphatidyli-nositol 3-kinase-dependent mechanism. Endocrinology 147, 2550-2556.